{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:54:13Z","timestamp":1789998853969,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["20H03828"],"award-info":[{"award-number":["20H03828"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21K09457"],"award-info":[{"award-number":["21K09457"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ama221416h0002"],"award-info":[{"award-number":["23ama221416h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Minoru Sano Memorial Fund, Japan","award":["23I326218"],"award-info":[{"award-number":["23I326218"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-70228-6","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:02:25Z","timestamp":1724857345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive serum glycopeptide spectra analysis to identify early-stage epithelial ovarian cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Mikio","family":"Mikami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masae","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisamori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Katahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"70228_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA: Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA: Cancer J. Clin."},{"key":"70228_CR2","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1002\/cncr.34479","volume":"128","author":"KA Cronin","year":"2022","unstructured":"Cronin, K. A. et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer 128, 4251\u20134284 (2022).","journal-title":"Cancer"},{"key":"70228_CR3","unstructured":"Cancer Research UK, Ovarian cancer survival statistics, https:\/\/www.cancerresearchuk.org\/about-cancer\/ovarian-cancer\/survival, accessed on Feb. 14, 2023."},{"key":"70228_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00259-017-3638-z","volume":"44","author":"B Khiewvan","year":"2017","unstructured":"Khiewvan, B. et al. An update on the role of PET\/CT and PET\/MRI in ovarian cancer. Eur. J. Nuclear Med. Mol. Imaging 44, 1079\u20131091 (2017).","journal-title":"Eur. J. Nuclear Med. Mol. Imaging"},{"key":"70228_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1148\/radiol.2332031800","volume":"233","author":"S Sironi","year":"2004","unstructured":"Sironi, S. et al. Integrated FDG PET\/CT in patients with persistent ovarian cancer: Correlation with histologic findings. Radiology 233, 433\u2013440 (2004).","journal-title":"Radiology"},{"key":"70228_CR6","unstructured":"Cancer Research UK, Breaking down barriers to cancer screening, https:\/\/news.cancerresearchuk.org\/2022\/09\/23\/health-inequalities-breaking-down-barriers-to-cancer-screening\/, accessed on July. 13, 2024."},{"key":"70228_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","volume":"104","author":"T Van Gorp","year":"2011","unstructured":"Van Gorp, T. et al. HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation of the Risk of Ovarian Malignancy Algorithm. Br. J. Cancer 104, 863\u2013870 (2011).","journal-title":"Br. J. Cancer"},{"key":"70228_CR8","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1940-6207.CAPR-11-0378","volume":"4","author":"O Dorigo","year":"2011","unstructured":"Dorigo, O. & Berek, J. S. Personalizing CA125 levels for ovarian cancer screening. Cancer Prevent. Res. 4, 1356\u20131359 (2011).","journal-title":"Cancer Prevent. Res."},{"key":"70228_CR9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys, S. S. et al. Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. Jama 305, 2295\u20132303 (2011).","journal-title":"Jama"},{"key":"70228_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2016.08.334","volume":"143","author":"PF Pinsky","year":"2016","unstructured":"Pinsky, P. F. et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol. Oncol. 143, 270\u2013275 (2016).","journal-title":"Gynecol. Oncol."},{"key":"70228_CR11","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.3390\/cancers14235867","volume":"14","author":"C Rogmans","year":"2022","unstructured":"Rogmans, C. et al. Nectin-4 as blood-based biomarker enables detection of early ovarian cancer stages. Cancers 14, 5867 (2022).","journal-title":"Cancers"},{"key":"70228_CR12","doi-asserted-by":"publisher","first-page":"1038835","DOI":"10.3389\/fonc.2022.1038835","volume":"12","author":"W Sakares","year":"2022","unstructured":"Sakares, W. et al. Accuracy of CCL20 expression level as a liquid biopsy-based diagnostic biomarker for ovarian carcinoma. Front. Oncol. 12, 1038835 (2022).","journal-title":"Front. Oncol."},{"key":"70228_CR13","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.3390\/cancers13215563","volume":"13","author":"C Rogmans","year":"2021","unstructured":"Rogmans, C. et al. ADAM17-A potential blood-based biomarker for detection of early-stage ovarian cancer. Cancers 13, 5563 (2021).","journal-title":"Cancers"},{"key":"70228_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/ijc.33866","volume":"150","author":"AY Berghuis","year":"2022","unstructured":"Berghuis, A. Y., Pijnenborg, J. F. A., Boltje, T. J. & Pijnenborg, J. M. A. Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment. Int. J. Cancer 150, 678\u2013687 (2022).","journal-title":"Int. J. Cancer"},{"key":"70228_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698312","volume":"12","author":"C Qiu","year":"2021","unstructured":"Qiu, C. et al. Serum Anti-PDLIM1 autoantibody as diagnostic marker in ovarian cancer. Front. Immunol. 12, 698312 (2021).","journal-title":"Front. Immunol."},{"key":"70228_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ncrna.2022.07.004","volume":"7","author":"A Beilerli","year":"2022","unstructured":"Beilerli, A. et al. Circulating ciRS-7 as a potential non-invasive biomarker for epithelial ovarian cancer: An investigative study. Non-Coding RNA Res. 7, 197\u2013204 (2022).","journal-title":"Non-Coding RNA Res."},{"key":"70228_CR17","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.3390\/cancers14133077","volume":"14","author":"KLM Boylan","year":"2022","unstructured":"Boylan, K. L. M. et al. Development of a multiprotein classifier for the detection of early stage ovarian cancer. Cancers 14, 3077 (2022).","journal-title":"Cancers"},{"key":"70228_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.786154","volume":"12","author":"A Gockley","year":"2022","unstructured":"Gockley, A. et al. A translational model to improve early detection of epithelial ovarian cancers. Front. Oncol. 12, 786154 (2022).","journal-title":"Front. Oncol."},{"key":"70228_CR19","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/cancers14071757","volume":"14","author":"U Gyllensten","year":"2022","unstructured":"Gyllensten, U. et al. Next generation plasma proteomics identifies high-precision biomarker candidates for ovarian cancer. Cancers 14, 1757 (2022).","journal-title":"Cancers"},{"key":"70228_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/cancers13020325","volume":"13","author":"C Walker","year":"2021","unstructured":"Walker, C. et al. Automated assay of a four-protein biomarker panel for improved detection of ovarian cancer. Cancers 13, 325 (2021).","journal-title":"Cancers"},{"key":"70228_CR21","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/jpm12081211","volume":"12","author":"MM Ahamad","year":"2022","unstructured":"Ahamad, M. M. et al. Early-stage detection of ovarian cancer based on clinical data using machine learning approaches. J. Personal. Med. 12, 1211 (2022).","journal-title":"J. Personal. Med."},{"key":"70228_CR22","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1038\/s41467-018-06434-4","volume":"9","author":"A Yokoi","year":"2018","unstructured":"Yokoi, A. et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat. Commun. 9, 4319 (2018).","journal-title":"Nat. Commun."},{"issue":"21","key":"70228_CR23","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-22-1113","volume":"28","author":"E Irajizad","year":"2022","unstructured":"Irajizad, E. et al. A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clin. Cancer Res. 28(21), 4669\u20134676. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1113 (2022).","journal-title":"Clin. Cancer Res."},{"key":"70228_CR24","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.radcr.2022.05.015","volume":"17","author":"E Negr\u00e3o","year":"2022","unstructured":"Negr\u00e3o, E. et al. Ovarian clear cell carcinoma arising in a large endometrioma - A case report with pathological correlation and literature review. Radiol. Case Rep. 17, 2806\u20132811 (2022).","journal-title":"Radiol. Case Rep."},{"key":"70228_CR25","first-page":"788","volume":"100","author":"SC Modesitt","year":"2002","unstructured":"Modesitt, S. C., Tortolero-Luna, G., Robinson, J. B., Gershenson, D. M. & Wolf, J. K. Ovarian and extraovarian endometriosis-associated cancer. Obstet. Gynecol. 100, 788\u2013795 (2002).","journal-title":"Obstet. Gynecol."},{"key":"70228_CR26","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre, L. A. et al. Ovarian cancer statistics, 2018. CA: Cancer J. Clin. 68, 284\u2013296 (2018).","journal-title":"CA: Cancer J. Clin."},{"key":"70228_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","volume":"20","author":"HJ Mackay","year":"2010","unstructured":"Mackay, H. J. et al. Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer. Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc. 20, 945\u2013952 (2010).","journal-title":"Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc."},{"key":"70228_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ygyno.2011.05.009","volume":"122","author":"YY Lee","year":"2011","unstructured":"Lee, Y. Y. et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis. Gynecol. Oncol. 122, 541\u2013547 (2011).","journal-title":"Gynecol. Oncol."},{"key":"70228_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.12688\/f1000research.13863.2","volume":"7","author":"F Leung","year":"2018","unstructured":"Leung, F. et al. Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. F1000Research 7, 189 (2018).","journal-title":"F1000Research"},{"key":"70228_CR30","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3390\/biomedicines10112683","volume":"10","author":"N Kawahara","year":"2022","unstructured":"Kawahara, N. et al. The endometriotic neoplasm algorithm for risk assessment (e-NARA) index sheds light on the discrimination of endometriosis-associated ovarian cancer from ovarian endometrioma. Biomedicines 10, 2683 (2022).","journal-title":"Biomedicines"},{"key":"70228_CR31","doi-asserted-by":"publisher","first-page":"8913","DOI":"10.3390\/ijms21238913","volume":"21","author":"M Higashi","year":"2020","unstructured":"Higashi, M. et al. A potential serum N-glycan biomarker for hepatitis C virus-related early-stage hepatocellular carcinoma with liver cirrhosis. Int. J. Mol. Sci. 21, 8913 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"70228_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bbrc.2008.06.124","volume":"374","author":"K Tanabe","year":"2008","unstructured":"Tanabe, K. et al. Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma patients. Biochem. Biophys. Res. Commun. 374, 219\u2013225 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"70228_CR33","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acs.jproteome.5b01145","volume":"15","author":"K Tanabe","year":"2016","unstructured":"Tanabe, K., Kitagawa, K., Kojima, N. & Iijima, S. Multifucosylated alpha-1-acid glycoprotein as a novel marker for hepatocellular carcinoma. J. Proteome Res. 15, 2935\u20132944 (2016).","journal-title":"J. Proteome Res."},{"key":"70228_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-018-4252-6","volume":"18","author":"E Shinozaki","year":"2018","unstructured":"Shinozaki, E. et al. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: A novel colorectal cancer marker. BMC Cancer 18, 406 (2018).","journal-title":"BMC Cancer"},{"key":"70228_CR35","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.3390\/ijms22105222","volume":"22","author":"C Gabriele","year":"2021","unstructured":"Gabriele, C., Prestagiacomo, L. E., Cuda, G. & Gaspari, M. Mass spectrometry-based glycoproteomics and prostate cancer. Int. J. Mol. Sci. 22, 5222 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"70228_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ygyno.2015.10.012","volume":"139","author":"M Mikami","year":"2015","unstructured":"Mikami, M. et al. Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma. Gynecol. Oncol. 139, 520\u2013528 (2015).","journal-title":"Gynecol. Oncol."},{"key":"70228_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers11050591","volume":"11","author":"M Hayashi","year":"2019","unstructured":"Hayashi, M. et al. Comprehensive serum glycopeptide spectra analysis (CSGSA): A potential new tool for early detection of ovarian cancer. Cancers 11, 591 (2019).","journal-title":"Cancers"},{"key":"70228_CR38","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/cancers12092374","volume":"12","author":"K Matsuo","year":"2020","unstructured":"Matsuo, K. et al. Utility of comprehensive serum glycopeptide spectra analysis (CSGSA) for the detection of early stage epithelial ovarian cancer. Cancers 12, 2374 (2020).","journal-title":"Cancers"},{"key":"70228_CR39","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3390\/cancers12092373","volume":"12","author":"K Tanabe","year":"2020","unstructured":"Tanabe, K. et al. Comprehensive serum glycopeptide spectra analysis combined with artificial intelligence (CSGSA-AI) to diagnose early-stage ovarian cancer. Cancers 12, 2373 (2020).","journal-title":"Cancers"},{"key":"70228_CR40","doi-asserted-by":"publisher","first-page":"5\u00a05","DOI":"10.1111\/1471-0528.14711","volume":"125","author":"VH Eisenberg","year":"2018","unstructured":"Eisenberg, V. H., Weil, C., Chodick, G. & Shalev, V. Epidemiology of endometriosis: A large population-based database study from a healthcare provider with 2 million members. BJOG: Int. J. Obstet. Gynaecol 125, 5\u00a05-62 (2018).","journal-title":"BJOG: Int. J. Obstet. Gynaecol"},{"key":"70228_CR41","doi-asserted-by":"publisher","first-page":"e13095","DOI":"10.1111\/aji.13095","volume":"81","author":"H Greenbaum","year":"2019","unstructured":"Greenbaum, H., Weil, C., Chodick, G., Shalev, V. & Eisenberg, V. H. Evidence for an association between endometriosis, fibromyalgia, and autoimmune diseases. Am. J. Reprodu. Immunol. 81, e13095 (2019).","journal-title":"Am. J. Reprodu. Immunol."},{"issue":"591","key":"70228_CR42","first-page":"e591","volume":"219","author":"O Yu","year":"2018","unstructured":"Yu, O. et al. A US population-based study of uterine fibroid diagnosis incidence, trends, and prevalence: 2005 through 2014. Am. J. Obstet. Gynecol. 219(591), e591-591.e598 (2018).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"70228_CR43","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1046\/j.1469-0705.1994.04050414.x","volume":"4","author":"H Schulman","year":"1994","unstructured":"Schulman, H. et al. Prevalence in a volunteer population of pelvic cancer detected with transvaginal ultrasound and color flow Doppler. Ultrasound obstet. Gynecol.: Off. J. Int. Soc. Ultrasound Obstet. Gynecol. 4, 414\u2013420 (1994).","journal-title":"Ultrasound obstet. Gynecol.: Off. J. Int. Soc. Ultrasound Obstet. Gynecol."},{"key":"70228_CR44","doi-asserted-by":"publisher","first-page":"13831","DOI":"10.1038\/s41598-019-50304-y","volume":"9","author":"H Mikami","year":"2019","unstructured":"Mikami, H. et al. A multicentre clinical validation of aminoindex cancer screening (AICS). Sci. Rep. 9, 13831 (2019).","journal-title":"Sci. Rep."},{"key":"70228_CR45","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.3390\/molecules26196003","volume":"26","author":"D Vir\u00e1g","year":"2021","unstructured":"Vir\u00e1g, D. et al. Altered glycosylation of human alpha-1-Acid glycoprotein as a biomarker for malignant melanoma. Molecules 26, 6003 (2021).","journal-title":"Molecules"},{"key":"70228_CR46","doi-asserted-by":"publisher","first-page":"14503","DOI":"10.1038\/s41598-019-51021-2","volume":"9","author":"T Yokobori","year":"2019","unstructured":"Yokobori, T. et al. Fucosylated \u03b1(1)-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. Sci. Rep. 9, 14503 (2019).","journal-title":"Sci. Rep."},{"key":"70228_CR47","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1021\/acs.jproteome.5b00792","volume":"14","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. ESI-LC-MS method for haptoglobin fucosylation analysis in hepatocellular carcinoma and liver cirrhosis. J. Proteome Res. 14, 5388\u20135395 (2015).","journal-title":"J. Proteome Res."},{"key":"70228_CR48","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/elps.201500518","volume":"37","author":"S Weiz","year":"2016","unstructured":"Weiz, S. et al. Acute-phase glycoprotein N-glycome of ovarian cancer patients analyzed by CE-LIF. Electrophoresis 37, 1461\u20131467 (2016).","journal-title":"Electrophoresis"},{"key":"70228_CR49","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1039\/C6MB00559D","volume":"12","author":"SH Lee","year":"2016","unstructured":"Lee, S. H. et al. Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC\/MS and LC\/MS\/MS. Mol. BioSyst. 12, 3611\u20133621 (2016).","journal-title":"Mol. BioSyst."},{"key":"70228_CR50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10719-016-9653-7","volume":"33","author":"S Takahashi","year":"2016","unstructured":"Takahashi, S. et al. Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: Possible implication for the differential diagnosis of cancer. Glycoconjugate J. 33, 471\u2013482 (2016).","journal-title":"Glycoconjugate J."},{"key":"70228_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cca.2018.09.001","volume":"487","author":"K Morishita","year":"2018","unstructured":"Morishita, K. et al. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis. Clinica chimica acta: Int. J. Clin. Chem. 487, 84\u201389 (2018).","journal-title":"Clinica chimica acta: Int. J. Clin. Chem."},{"key":"70228_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/proteomes8030026","volume":"8","author":"J Chantaraamporn","year":"2020","unstructured":"Chantaraamporn, J. et al. Glycoproteomic analysis reveals aberrant expression of complement C9 and fibronectin in the plasma of patients with colorectal cancer. Proteomes 8, 26 (2020).","journal-title":"Proteomes"},{"key":"70228_CR53","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1349-7006.2010.01818.x","volume":"102","author":"Y Murakoshi","year":"2011","unstructured":"Murakoshi, Y. et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci. 102, 630\u2013638 (2011).","journal-title":"Cancer Sci."},{"key":"70228_CR54","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1002\/pmic.200401321","volume":"5","author":"N Ahmed","year":"2005","unstructured":"Ahmed, N. et al. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 5, 4625\u20134636 (2005).","journal-title":"Proteomics"},{"key":"70228_CR55","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/430611b","volume":"430","author":"J Villanueva","year":"2004","unstructured":"Villanueva, J. & Tempst, P. OvaCheck: Let\u2019s not dismiss the concept. Nature 430, 611 (2004).","journal-title":"Nature"},{"key":"70228_CR56","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s10147-021-01914-y","volume":"26","author":"E Miyagi","year":"2021","unstructured":"Miyagi, E. et al. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary. Int. J. Clin. Oncol. 26, 1336\u20131344 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"70228_CR57","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1021\/acs.analchem.1c04302","volume":"94","author":"M Sogabe","year":"2022","unstructured":"Sogabe, M. et al. Sensitive new assay system for serum wisteria floribunda agglutinin-reactive ceruloplasmin that distinguishes ovarian clear cell carcinoma from endometrioma. Anal. Chem. 94, 2476\u20132484 (2022).","journal-title":"Anal. Chem."},{"key":"70228_CR58","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 397, 2182\u20132193 (2021).","journal-title":"Lancet"},{"key":"70228_CR59","unstructured":"Development of the AI system for early detection of ovarian cancer using cancer specific glycoprotein markers and peaks from comprehensive serum glycopeptide spectra analysis (CSGSA), https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000057004, accessed on Feb. 14, 2023."},{"key":"70228_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat, J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet.: Off. Organ Int. Federation Gynaecol. Obstet. 124, 1\u20135 (2014).","journal-title":"Int. J. Gynaecol. Obstet.: Off. Organ Int. Federation Gynaecol. Obstet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70228-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:09:50Z","timestamp":1724857790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70228-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70228"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70228-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KT(Kazuhiro Tanabe), TK(Tomoko Katahira), and CH are employed by LSI Medience Corporation, which can provide ovarian cancer screening. MM and LSI Medience Corporation applied for a patent related to this research in Japan (2019\u2013108992). The remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20000"}}